Mohammad Hirmand

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.6K citations · Full text

Medicine, Oncology, Pharmacology +14

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

Howard I. Scher, Tomasz M. Beer, Celestia S. Higano et al. · The Lancet · 2010 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

Glenn Heller, Robert McCormack, Thian Kheoh et al. · Journal of Clinical Oncology · 2017 · 230 citations

Medicine, Oncology, Genitourinary Oncology +16

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

Karim Fizazi, Howard I. Scher, Kurt Miller et al. · The Lancet Oncology · 2014 · 207 citations

Medicine, Oncology, Pharmacotherapy +13

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Cora N. Sternberg, Johann S. de Bono, K.N. Chi et al. · Annals of Oncology · 2014 · 128 citations · Full text

Medicine, Oncology, Pharmacology +16